The Beginning of the End
The Beginning of the End
November 16, 2021
•
43m
•
Episode Ranking: 21/100
TOPICS: Disruptive Innovation Evidence-based Science Human Understanding Of Universe
Episode Description
This episode features insights from two Theranos lab directors, one who had no direct contact with Elizabeth Holmes or the lab, and another who voided over 50,000 Theranos tests post a damaging government inspection. We also hear from a frustrated investor cut off by Holmes after seeking basic company info. Plus, a surprising update from prosecutor Jeffrey Schenk - the prosecution may rest its case this week, just 10 weeks into the trial with only 24 out of 181 potential witnesses having testified.
Ideabrix Summary
In 'The Beginning of the End' episode of 'The Dropout,' the narrative continues to unravel the complexities of the Theranos scandal, focusing on the testimonies of two lab directors and an investor. The episode begins with a recap of the falsified documents and sets the stage for the prosecution nearing the end of presenting its case. The prosecution's strategy appears to be accelerating towards a conclusion, mindful of the dwindling number of jurors and the approaching holiday season amidst the COVID-19 pandemic.
The first lab director discussed is Dr. Lynette Sawyer, who, despite holding the title, never visited Theranos's lab nor met Elizabeth Holmes in person. Her testimony reveals the peculiarities of her role, which was limited to electronically signing documents without the ability to investigate or edit them, highlighting the lack of oversight and accountability within Theranos's operations. Dr. Sawyer's discomfort with the lack of transparency and her inability to perform her duties effectively led to her resignation after six months.
The second lab director, Dr. Kingshuk Das, took the stand to describe the aftermath of a scathing report from the Centers for Medicare and Medicaid Services (CMS), which found significant violations in Theranos's lab practices. Dr. Das's testimony paints a picture of a lab in disarray, with failed quality controls and patient results being reported despite clear failures. His decision to void tens of thousands of tests is a pivotal moment, showing both the gravity of Theranos's issues and the company's eventual acknowledgment of the flawed results.
The episode also features the testimony of investor Alan Eisenman, who invested $1 million based on the promises made by Elizabeth Holmes and Theranos. His narrative reflects a journey from initial excitement to growing frustration as Theranos's communication became increasingly evasive. Eisenman's attempts to obtain information about his investment were met with hostility, and his additional investment of $100,000 was based on the company's misleading success portrayed in the media and the opportunity to have a 'seat at the table' for future gains. His experience culminates in a total loss of his investment, underscoring the personal financial impact of Theranos's deceptive practices.
The first lab director discussed is Dr. Lynette Sawyer, who, despite holding the title, never visited Theranos's lab nor met Elizabeth Holmes in person. Her testimony reveals the peculiarities of her role, which was limited to electronically signing documents without the ability to investigate or edit them, highlighting the lack of oversight and accountability within Theranos's operations. Dr. Sawyer's discomfort with the lack of transparency and her inability to perform her duties effectively led to her resignation after six months.
The second lab director, Dr. Kingshuk Das, took the stand to describe the aftermath of a scathing report from the Centers for Medicare and Medicaid Services (CMS), which found significant violations in Theranos's lab practices. Dr. Das's testimony paints a picture of a lab in disarray, with failed quality controls and patient results being reported despite clear failures. His decision to void tens of thousands of tests is a pivotal moment, showing both the gravity of Theranos's issues and the company's eventual acknowledgment of the flawed results.
The episode also features the testimony of investor Alan Eisenman, who invested $1 million based on the promises made by Elizabeth Holmes and Theranos. His narrative reflects a journey from initial excitement to growing frustration as Theranos's communication became increasingly evasive. Eisenman's attempts to obtain information about his investment were met with hostility, and his additional investment of $100,000 was based on the company's misleading success portrayed in the media and the opportunity to have a 'seat at the table' for future gains. His experience culminates in a total loss of his investment, underscoring the personal financial impact of Theranos's deceptive practices.
Subscribe to our Premium Plan to learn more.
Discover more about this episode
Summary and conclusion
Key takeaways
Quotes
Vocabulary
Mentioned media
Mentioned people
